With the aim of further characterizing the potential combinatory effects of BRD4 inhibition and a standard treatment for MDS, HEL, and U937 cells were treated with JQ1 and azacitidine for 48 h. The gene discussed is BRD4; the disease is myelodysplastic syndrome.